This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNext Science（NXSC.F）株式概要ネクストサイエンス社は、北米、オーストラリア、ニュージーランドにおいて、バイオフィルム、常在細菌、真菌、ウイルス、感染症による人の健康問題を解決する技術の研究、開発、商品化に取り組んでいる。 詳細NXSC.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析意味のある時価総額がありません ( $293K )キャッシュランウェイが1年未満である 過去5年間で収益は年間2.2%減少しました。 マイナスの株主資本 +1 さらなるリスクすべてのリスクチェックを見るNXSC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.00199.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16m99m2016201920222025202620282031Revenue US$98.7mEarnings US$13.4mAdvancedSet Fair ValueView all narrativesNext Science Limited 競合他社InVitro InternationalSymbol: OTCPK:IVROMarket cap: US$1.7mStandard Dental LabsSymbol: OTCPK:TUTHMarket cap: US$4.6mVycor MedicalSymbol: OTCPK:VYCOMarket cap: US$2.3mWORK Medical Technology GroupSymbol: NasdaqCM:WOKMarket cap: US$195.2k価格と性能株価の高値、安値、推移の概要Next Science過去の株価現在の株価US$0.00152週高値US$0.1152週安値US$0.0002ベータ1.691ヶ月の変化-98.14%3ヶ月変化-98.82%1年変化-98.82%3年間の変化-99.80%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025お知らせ • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.お知らせ • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025お知らせ • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.お知らせ • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024最新情報をもっと見るRecent updatesお知らせ • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025お知らせ • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.お知らせ • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025お知らせ • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.お知らせ • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024お知らせ • Jul 26Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Jul 10Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024お知らせ • Apr 23Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024お知らせ • Mar 04Next Science Limited, Annual General Meeting, May 03, 2024Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time.お知らせ • Feb 16Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024お知らせ • Nov 01Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,571,429 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,851,024 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,244,504 Price\Range: AUD 0.42 Transaction Features: Reserved Share Offering; Subsequent Direct Listingお知らせ • Oct 24Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive DirectorNext Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD).お知らせ • Aug 23Next Science Limited Announces Board ChangesNext Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.お知らせ • Jun 30+ 1 more updateNext Science Limited Appoints Marc Zimmerman as Chief Financial OfficerThe Board of Next Science Limited appointment and commencement of Marc Zimmerman as Chief Financial Officer.お知らせ • Jun 29Next Science Limited Commercialising Its Proprietary Xbiotm Suite of ProductsNext Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.お知らせ • Jun 17+ 1 more updateNext Science Limited Announces Executive ChangesNext Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July. New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.お知らせ • Feb 10+ 4 more updatesNext Science Limited to Report Q2, 2023 Results on Jul 31, 2023Next Science Limited announced that they will report Q2, 2023 results on Jul 31, 2023株主還元NXSC.FUS Medical EquipmentUS 市場7D400.0%4.4%1.0%1Y-98.8%-17.9%28.7%株主還元を見る業界別リターン: NXSC.F過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: NXSC.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is NXSC.F's price volatile compared to industry and market?NXSC.F volatilityNXSC.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.7%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: NXSC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のNXSC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2012n/an/awww.nextscience.comネクストサイエンス社は、北米、オーストラリア、ニュージーランドにおいて、バイオフィルム、常在細菌、真菌、ウイルス、感染症によって引き起こされる人の健康上の問題を解決する技術の研究、開発、商業化に従事している。抗菌創傷ジェル「SURGX」、ニキビ用ジェル、口腔洗浄剤、創傷洗浄剤「BACTISURE」、創傷治癒を促進する湿潤創傷環境を維持することで創傷管理を行う抗菌創傷ジェル「BlastX」、創傷から微生物を含む残渣を洗浄・除去するための「XPERIENCE」などを提供している。同社は2012年に設立され、オーストラリアのシドニーに本社を置いている。もっと見るNext Science Limited 基礎のまとめNext Science の収益と売上を時価総額と比較するとどうか。NXSC.F 基礎統計学時価総額US$292.63k収益（TTM）-US$9.43m売上高(TTM)US$22.07m0.0xP/Sレシオ0.0xPER（株価収益率NXSC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NXSC.F 損益計算書（TTM）収益US$22.07m売上原価US$3.87m売上総利益US$18.20mその他の費用US$27.63m収益-US$9.43m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.032グロス・マージン82.48%純利益率-42.74%有利子負債／自己資本比率-849.6%NXSC.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/19 14:16終値2026/02/17 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Next Science Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025
お知らせ • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.
お知らせ • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025
お知らせ • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.
お知らせ • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024
お知らせ • Apr 11Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025
お知らせ • Mar 11Next Science Limited, Annual General Meeting, May 09, 2025Next Science Limited, Annual General Meeting, May 09, 2025.
お知らせ • Feb 07Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • Jan 20Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025
お知らせ • Jan 08Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former EmployeeNext Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings.
お知らせ • Oct 16Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024
お知らせ • Jul 26Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Jul 10Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024
お知らせ • Apr 23Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024
お知らせ • Mar 04Next Science Limited, Annual General Meeting, May 03, 2024Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time.
お知らせ • Feb 16Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024
お知らせ • Nov 01Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,571,429 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,851,024 Price\Range: AUD 0.42 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,244,504 Price\Range: AUD 0.42 Transaction Features: Reserved Share Offering; Subsequent Direct Listing
お知らせ • Oct 24Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive DirectorNext Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD).
お知らせ • Aug 23Next Science Limited Announces Board ChangesNext Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.
お知らせ • Jun 30+ 1 more updateNext Science Limited Appoints Marc Zimmerman as Chief Financial OfficerThe Board of Next Science Limited appointment and commencement of Marc Zimmerman as Chief Financial Officer.
お知らせ • Jun 29Next Science Limited Commercialising Its Proprietary Xbiotm Suite of ProductsNext Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.
お知らせ • Jun 17+ 1 more updateNext Science Limited Announces Executive ChangesNext Science Limited announced the appointment of Harry Thomas Hall, IV (commonly known as I.V.) as its new Managing Director and Chief Executive Officer (CEO). I.V. will commence as CEO on 10 July 2023. To ensure a comprehensive and smooth handover, current CEO, Judith Mitchell, will remain with the company until the end of July. New CEO - Harry Thomas Hall, IV (I.V.): Over the course of 28 years in the global medical device industry, I.V. has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ /DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a USD 3.2 billion platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide. I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School. I.V. will be relocating from Pennsylvania to be permanently based in Jacksonville, Florida.
お知らせ • Feb 10+ 4 more updatesNext Science Limited to Report Q2, 2023 Results on Jul 31, 2023Next Science Limited announced that they will report Q2, 2023 results on Jul 31, 2023
